CN115960184A - 一种溶血性曼氏杆菌a6血清型白细胞毒素抗原蛋白、其抗体及应用 - Google Patents
一种溶血性曼氏杆菌a6血清型白细胞毒素抗原蛋白、其抗体及应用 Download PDFInfo
- Publication number
- CN115960184A CN115960184A CN202211187275.1A CN202211187275A CN115960184A CN 115960184 A CN115960184 A CN 115960184A CN 202211187275 A CN202211187275 A CN 202211187275A CN 115960184 A CN115960184 A CN 115960184A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- serotype
- mannheimia
- lkt
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710170970 Leukotoxin Proteins 0.000 title claims abstract description 101
- 241001293418 Mannheimia haemolytica Species 0.000 title claims abstract description 45
- 230000002949 hemolytic effect Effects 0.000 claims abstract description 34
- 241001293415 Mannheimia Species 0.000 claims abstract description 32
- 238000001514 detection method Methods 0.000 claims abstract description 16
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 229960002685 biotin Drugs 0.000 claims description 20
- 235000020958 biotin Nutrition 0.000 claims description 20
- 239000011616 biotin Substances 0.000 claims description 20
- 238000005406 washing Methods 0.000 claims description 15
- 238000003118 sandwich ELISA Methods 0.000 claims description 14
- 206010003445 Ascites Diseases 0.000 claims description 12
- 238000002965 ELISA Methods 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000007865 diluting Methods 0.000 claims description 7
- 238000010790 dilution Methods 0.000 claims description 7
- 239000012895 dilution Substances 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108010090804 Streptavidin Proteins 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 239000012089 stop solution Substances 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000007918 pathogenicity Effects 0.000 claims description 4
- 210000004988 splenocyte Anatomy 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000031700 light absorption Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000012488 sample solution Substances 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 abstract description 14
- 238000006386 neutralization reaction Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000009465 prokaryotic expression Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ASVYXWZOBCRSFB-UHFFFAOYSA-N C(C)S(=O)(O)=S.OCCN1CCNCC1 Chemical compound C(C)S(=O)(O)=S.OCCN1CCNCC1 ASVYXWZOBCRSFB-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101000984128 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101000984148 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001038258 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001038259 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001134430 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001134431 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001134432 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001134433 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001135001 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001135002 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001135003 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001135004 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001135010 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001135014 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 101001135012 Mannheimia haemolytica Leukotoxin Proteins 0.000 description 1
- 241001354481 Mansonia <mosquito genus> Species 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229940124939 Pox vaccine Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- -1 i.e. Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
布局 | 1 | 2 | 3 |
A | P1 | P1 | P1 |
B | P2 | P2 | P2 |
C | P3 | P3 | P3 |
D | P4 | P4 | P4 |
E | P5 | P5 | P5 |
F | P6 | P6 | P6 |
G | LKT | LKT | LKT |
H | Control | Control | Control |
布局 | 1 | 2 | 3 |
A | 0.425 | 0.471 | 0.41 |
B | 0.406 | 0.376 | 0.391 |
C | 0.396 | 0.386 | 0.351 |
D | 0.415 | 0.403 | 0.372 |
E | 0.206 | 0.39 | 0.44 |
F | 0.177 | 0.346 | 0.364 |
G | 1.176 | 1.218 | 1.233 |
H | 0.249 | 0.132 | 0.272 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211187275.1A CN115960184B (zh) | 2022-09-28 | 2022-09-28 | 一种溶血性曼氏杆菌a6血清型白细胞毒素抗原蛋白、其抗体及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211187275.1A CN115960184B (zh) | 2022-09-28 | 2022-09-28 | 一种溶血性曼氏杆菌a6血清型白细胞毒素抗原蛋白、其抗体及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115960184A true CN115960184A (zh) | 2023-04-14 |
CN115960184B CN115960184B (zh) | 2023-12-12 |
Family
ID=87351701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211187275.1A Active CN115960184B (zh) | 2022-09-28 | 2022-09-28 | 一种溶血性曼氏杆菌a6血清型白细胞毒素抗原蛋白、其抗体及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115960184B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1179181A (zh) * | 1995-02-10 | 1998-04-15 | 萨斯喀彻温大学 | GnRH-白细胞毒素嵌合体 |
US6096320A (en) * | 1990-08-22 | 2000-08-01 | University Of Saskatchewan | Vaccines with chimeric protein comprising gamma-interferon and leukotoxin derived from pasteurella haemolytica |
CN1377369A (zh) * | 1999-08-31 | 2002-10-30 | 联邦科学和工业研究组织 | 莫拉氏菌属的疫苗抗原 |
US20140170190A1 (en) * | 2012-11-08 | 2014-06-19 | Merial Limited | Attenuated Mannheimia haemolytica Vaccines and Methods of Making and Use |
CN105664148A (zh) * | 2016-01-25 | 2016-06-15 | 华南农业大学 | 一种基因工程亚单位混合疫苗及其制备方法和应用 |
CN112190705A (zh) * | 2020-09-25 | 2021-01-08 | 广州源博医药科技有限公司 | 一种rsv-sh亚单位疫苗及其制备方法和应用 |
CN113249503A (zh) * | 2021-05-21 | 2021-08-13 | 华中农业大学 | 用于检测溶血性曼氏杆菌的lamp引物组及方法 |
CN113490506A (zh) * | 2019-01-30 | 2021-10-08 | 法国诗华大药厂 | 灭活的apxia、apxiia和apxiiia毒素 |
-
2022
- 2022-09-28 CN CN202211187275.1A patent/CN115960184B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096320A (en) * | 1990-08-22 | 2000-08-01 | University Of Saskatchewan | Vaccines with chimeric protein comprising gamma-interferon and leukotoxin derived from pasteurella haemolytica |
CN1179181A (zh) * | 1995-02-10 | 1998-04-15 | 萨斯喀彻温大学 | GnRH-白细胞毒素嵌合体 |
CN1377369A (zh) * | 1999-08-31 | 2002-10-30 | 联邦科学和工业研究组织 | 莫拉氏菌属的疫苗抗原 |
US20140170190A1 (en) * | 2012-11-08 | 2014-06-19 | Merial Limited | Attenuated Mannheimia haemolytica Vaccines and Methods of Making and Use |
CN105664148A (zh) * | 2016-01-25 | 2016-06-15 | 华南农业大学 | 一种基因工程亚单位混合疫苗及其制备方法和应用 |
CN113490506A (zh) * | 2019-01-30 | 2021-10-08 | 法国诗华大药厂 | 灭活的apxia、apxiia和apxiiia毒素 |
CN112190705A (zh) * | 2020-09-25 | 2021-01-08 | 广州源博医药科技有限公司 | 一种rsv-sh亚单位疫苗及其制备方法和应用 |
CN113249503A (zh) * | 2021-05-21 | 2021-08-13 | 华中农业大学 | 用于检测溶血性曼氏杆菌的lamp引物组及方法 |
Non-Patent Citations (6)
Title |
---|
CAROLINA GUZMÁN-BRAMBILA 等: ""LKTA and PlpE small fragments fusion protein protect against Mannheimia haemolytica challenge"", 《RESEARCH IN VETERINARY SCIENCE》, vol. 93, no. 3, pages 1293 - 1300, XP055490179, DOI: 10.1016/j.rvsc.2012.07.004 * |
DAVIES, R.L.等: ""Mannheimia haemolytica strain PH388 leukotoxin (lktA) gene, lktA1.3 allele, complete cds"", 《GENBANK》, pages 314504 * |
DOYLE, S等: ""Leukotoxin [Mannheimia haemolytica]"", 《GENBANK》, pages 59834 * |
F A LAINSON: ""Characterization of epitopes involved in the neutralization of Pasteurella haemolytica serotype A1 leukotoxin"", 《MICROBIOLOGY (READING)》, vol. 142, no. 9, pages 2499 - 2507 * |
李奕欣 等: ""牛溶血性曼氏杆菌白细胞毒素、脂蛋白E和外膜蛋白A的免疫原性研究"", 《中国预防兽医学报》, vol. 43, no. 7, pages 753 - 758 * |
陆奕彤 等: ""溶血性曼氏杆菌重要抗原的免疫原性分析"", 《江苏农业学报》, vol. 38, no. 2, pages 446 - 452 * |
Also Published As
Publication number | Publication date |
---|---|
CN115960184B (zh) | 2023-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107176977B (zh) | 牛支原体MbovP730蛋白在自然感染和疫苗免疫鉴别中的应用 | |
CN109970851B (zh) | Ccv病毒m蛋白的单抗及其制备方法、免疫胶体金试纸条的制备方法 | |
CN114736290B (zh) | 一种可以高精确度和敏感性识别猪伪狂犬病毒的纳米抗体、制备方法和应用 | |
CN114288402B (zh) | 一种基于反向疫苗学技术的猪肺炎支原体多表位基因工程亚单位疫苗的制备方法及其应用 | |
CN114276445A (zh) | 轮状病毒重组蛋白特异性抗体、质粒载体及方法 | |
CN110642927A (zh) | 一种蛋白在制备预防化脓隐秘杆菌感染的药物中的应用 | |
CN111621506B (zh) | 牛支原体分泌蛋白MbovP0145及其应用 | |
CN111548423B (zh) | 肺炎支原体融合抗原及其制备方法和应用 | |
CN116445448B (zh) | 鲍曼不动杆菌plpfp重组蛋白、制备方法及应用 | |
CN109541199B (zh) | 一种快速检测牛支原体的免疫胶体金试纸及其制备方法 | |
CN116478953A (zh) | 鲍曼不动杆菌DlaT重组蛋白、制备方法及应用 | |
CN115960184A (zh) | 一种溶血性曼氏杆菌a6血清型白细胞毒素抗原蛋白、其抗体及应用 | |
CN110903359B (zh) | 一种空肠弯曲菌重组蛋白及其单克隆抗体的制备 | |
CN110540599B (zh) | 基于肺炎克雷伯菌表面蛋白抗体的肺炎克雷伯菌Elisa检测试剂盒及制备方法 | |
CN113817027A (zh) | 一种牛疱疹病毒Ⅰ型gE蛋白胞外区的原核可溶性表达方法 | |
CN110540598B (zh) | 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法 | |
CN113698474A (zh) | 一种非洲猪瘟多克隆抗体及非洲猪瘟抗原检测试纸条 | |
CN115850523B (zh) | 一种单纯疱疹病毒ⅰ型特异性融合蛋白抗原及其制备方法和检测试剂盒 | |
CN113444157B (zh) | 猪鼻支原体外膜蛋白Mhr_0461在制备猪鼻支原体或其抗体检测试剂盒中的应用 | |
CN115785286B (zh) | 一种猪繁殖与呼吸综合征病毒的融合蛋白及其应用 | |
CN115785288B (zh) | 一种小反刍兽疫病毒h-n的抗原表位融合蛋白及其应用 | |
CN113461791B (zh) | 猪鼻支原体外膜蛋白Mhr_0493在制备猪鼻支原体或其抗体检测试剂盒中的应用 | |
CN115716867B (zh) | 一种V型分泌系统MisL展呈表达新型冠状病毒受体结合域B细胞表位抗原和应用 | |
CN116333063B (zh) | 胸膜肺炎放线杆菌的三个候选抗原及其应用 | |
CN113912711B (zh) | 能特异性识别多种沙门氏菌血清型的单克隆抗体及制备方法、检测试剂盒与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Guo Aizhen Inventor after: He Sun Inventor after: Han Rui Inventor after: Zhang Yuhao Inventor after: Yang Wenjing Inventor after: Yang Li Inventor after: Chen Jianguo Inventor after: Hu Changmin Inventor after: Chen Xi Inventor after: Chen Yingyu Inventor after: Hao Chengwu Inventor before: Guo Aizhen Inventor before: Zhang Yuhao Inventor before: Yang Wenjing Inventor before: Yang Li Inventor before: Chen Jianguo Inventor before: Hu Changmin Inventor before: Chen Xi Inventor before: Chen Yingyu |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230628 Address after: 430070 No. 1 Lion Rock street, Hongshan District, Hubei, Wuhan Applicant after: HUAZHONG AGRICULTURAL University Applicant after: Tiankang biopharmaceutical Co.,Ltd. Address before: 430070 No. 1 Lion Rock street, Hongshan District, Hubei, Wuhan Applicant before: HUAZHONG AGRICULTURAL University |
|
GR01 | Patent grant | ||
GR01 | Patent grant |